EMBC

Embecta Corp. (EMBC) | Rumor.io

Embecta

EMBC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,234

Bullish sentiment (50-day avg)77%

Price to earnings ratio4.03

Market capitalization336M

Earnings per share1.47

Dividend yield (TTM)0.67%

Revenue (annual)1.1B

Net income (annual)95.4M

Social

What share of all stock conversation is about EMBC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Aug 13

Embecta Corp. (EMBC) insiders have been making open-market purchases of the company's shares, with four key executives buying a total of 170,000 shares worth $468,813.
These purchases were made at prices ranging from $4.67 to $4.97, with the CEO and Director increasing their positions by 4% and 70% respectively.
The insider buying activity follows a 57.8% one-day collapse of the stock, with the CEO and Director buying at prices significantly lower than the 52-week high.

Generated by AI

Sentiment

Of the messages about EMBC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% +38.89	67.88% +0.32
Bearish	0%	0% 0	0% -38.89	32.12% -0.32

Bullish· May 7

Embecta Corp. ($EMBC) is trading at 3.0x average volume, with a 3.7% increase to $3.69 and 3.8M shares traded.
Insiders will have the option to buy stock tomorrow, which could lead to a surge in price and a potential close above $4.
The company's strong financials, including $47.2 million of FCF and $131.8 million gross profit, make it undervalued at a market cap of £211m.

Bearish· May 6

The company's dividend cut led to a massive overreaction, with the stock price plummeting 66% despite strong revenue and a business that isn't going anywhere.
The current price of $4 is a "market noise" and panic-driven oversold condition, detached from reality, given the company's strong cash flow, buyback program, and undervaluation.
Institutional investors own nearly all of the float, with only about 3-4 million shares owned by retail investors, making it difficult for short sellers to cover their positions and potentially leading to a short squeeze.

Generated by AI

Topics

Of the messages about EMBC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	76.92%	80.56%
Earnings	0%	0%	0%	4.1%
Technical Analysis	0%	0%	23.08%	4.75%
Controversies	0%	0%	0%	0.22%
Analysts	0%	0%	0%	0%
Macro	0%	0%	0%	10.37%

May 9

Embecta Corp. declared a quarterly cash dividend despite its share price continuing to decline.
Embecta Corp. reported its second-quarter fiscal 2024 financial results, but details of the report are not specified in the available information.
Embecta Corp.'s share price experienced a "gap up" after the company's earnings announcement.

Generated by AI

Community

Of the messages about EMBC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	9.09%	4.38%	9.81%
Newcomers	100%	90.91%	95.62%	90.19%

Aug 7

Newcomers are focusing on Embecta Corp.'s aggressive buyback strategy, which may indicate that management believes the stock is undervalued.
Investors are eagerly awaiting the earnings call for guidance, as it could provide insight into the company's future performance.
Embecta Corp.'s fiscal responsibility and debt repayment efforts are being highlighted, with some users anticipating a significant increase in the stock's value in the near future.

Generated by AI

PARSIPPANY, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events: Wells Fargo 2026 Healthcare ConferenceManagement will host one-on-one investor meetings on Wednesday, September 9, 2026, at the Encore Boston Harbor Hotel in Everett, Boston, MA.J.P. Morgan 4th Annu

29d agoYahoo Finance

The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

1mo agoSeeking Alpha

EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop

1mo agoMorningstar

EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit

1mo agoMorningstar

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

1mo agoMorningstar

Also Discussed

Investors talking about EMBC also mention

#	Name	Attention
1	Verra Mobility Corp. Class A Common StockVRRM	0%0
2	SGI Enhanced Market Leaders ETFLDRX	0%0
3	EMBCV - Embecta Corp.	——
4	Fiserv, Inc.FISV	0%-0.08
5	JPMorgan Healthcare Leaders ETFJDOC	0%0
6	Leslie's Inc.LESL	0%0
7	KraneShares 2X Long PDD Daily ETFKPDD	0%0
8	Direxion Daily MSFT Bull 2X SharesMSFU	0.37%new
9	Surf Air Mobility Inc.SRFM	0.14%-0.03
10	Edible Garden AG IncorporatedEDBL	0%0

Embecta Corp.

Healthcare
Medical Instruments & Supplies

Embecta Corp. is a medical device company focused on products and services that support diabetes management. Embecta Corp. offers a portfolio of pen needles, syringes, safety injection devices, and digital applications designed to help people living with diabetes use insulin and other injectable therapies. The company serves healthcare supply chains through wholesalers and distributors, with products reaching retail and institutional channels in the United States and international markets. Its offerings are used in routine diabetes care and medication delivery, making the company a specialized participant in the broader diabetes care market. Embecta Corp. is headquartered in Parsippany, New Jersey, and operates as a standalone healthcare company centered on essential injection and support solutions for people with diabetes.

Website

Location

300 Kimball Drive

Parsippany, NJ, 07054

United States

Social

What share of all stock conversation is about EMBC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Aug 13

Embecta Corp. (EMBC) insiders have been making open-market purchases of the company's shares, with four key executives buying a total of 170,000 shares worth $468,813.
These purchases were made at prices ranging from $4.67 to $4.97, with the CEO and Director increasing their positions by 4% and 70% respectively.
The insider buying activity follows a 57.8% one-day collapse of the stock, with the CEO and Director buying at prices significantly lower than the 52-week high.

Generated by AI

Sentiment

Of the messages about EMBC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% +38.89	67.88% +0.32
Bearish	0%	0% 0	0% -38.89	32.12% -0.32

Bullish· May 7

Embecta Corp. ($EMBC) is trading at 3.0x average volume, with a 3.7% increase to $3.69 and 3.8M shares traded.
Insiders will have the option to buy stock tomorrow, which could lead to a surge in price and a potential close above $4.
The company's strong financials, including $47.2 million of FCF and $131.8 million gross profit, make it undervalued at a market cap of £211m.

Bearish· May 6

The company's dividend cut led to a massive overreaction, with the stock price plummeting 66% despite strong revenue and a business that isn't going anywhere.
The current price of $4 is a "market noise" and panic-driven oversold condition, detached from reality, given the company's strong cash flow, buyback program, and undervaluation.
Institutional investors own nearly all of the float, with only about 3-4 million shares owned by retail investors, making it difficult for short sellers to cover their positions and potentially leading to a short squeeze.

Generated by AI

Topics

Of the messages about EMBC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	76.92%	80.56%
Earnings	0%	0%	0%	4.1%
Technical Analysis	0%	0%	23.08%	4.75%
Controversies	0%	0%	0%	0.22%
Analysts	0%	0%	0%	0%
Macro	0%	0%	0%	10.37%

May 9

Embecta Corp. declared a quarterly cash dividend despite its share price continuing to decline.
Embecta Corp. reported its second-quarter fiscal 2024 financial results, but details of the report are not specified in the available information.
Embecta Corp.'s share price experienced a "gap up" after the company's earnings announcement.

Generated by AI

Community

Of the messages about EMBC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	9.09%	4.38%	9.81%
Newcomers	100%	90.91%	95.62%	90.19%

Aug 7

Newcomers are focusing on Embecta Corp.'s aggressive buyback strategy, which may indicate that management believes the stock is undervalued.
Investors are eagerly awaiting the earnings call for guidance, as it could provide insight into the company's future performance.
Embecta Corp.'s fiscal responsibility and debt repayment efforts are being highlighted, with some users anticipating a significant increase in the stock's value in the near future.

Generated by AI

Embecta

Social

Aug 13

Sentiment

Bullish· May 7

Bearish· May 6

Topics

May 9

Community

Aug 7

News

Embecta director Milton Mayo sells $36,971 in shares

embecta to Participate in Investor Events

The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop

EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

Also Discussed

Embecta Corp.

Company Information

Location

Social

Aug 13

Sentiment

Bullish· May 7

Bearish· May 6

Topics

May 9

Community

Aug 7

News

Embecta director Milton Mayo sells $36,971 in shares

embecta to Participate in Investor Events

The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop

EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

Also Discussed